BACKGROUND: Secukinumab (SEC) is effective for ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in randomized trials, but real-life data are lacking. RESEARCH DESIGN AND METHODS: Real-life, prospective observational study on 169 consecutive outpatients at baseline (T0) and at 6 (T6) and 12 months (T12) after starting SEC (39 AS, 23%; 130 PsA, 77%). RESULTS: Significant improvement was seen at T6 and T12 for all clinical variables, including TJC, SJC, ESR, CRP, DAPSA, ASDAS-CRP, and BASDAI, as well as in patient-reported outcomes like VAS-pain. By multivariable regression analysis, in AS patients high BASDAI at T0 correlated with diagnostic delay (R2 = 0.4; p = 0.009) and peripheral joint involvement (R2 = 0.4; p = 0.04). During follow-up, reduction of BASDAI positively correlated with high ESR (R2 = 0.65; p = 0.04). ASDAS-CRP at T0 positively correlated with high ESR (R2 = 0.34; p = 0.004). Reduction of ASDAS-CRP from T0 to T6 correlated with current smoking status (R2 = 0.42; p = 0.003). In PsA patients, reduction of DAPSA score from T0 to T12 is negatively correlated with the presence of metabolic syndrome (R2 = 0.41; p = 0.0025). SEC was well tolerated; 10 patients discontinued treatment for non-severe adverse events. CONCLUSIONS: Secukinumab is effective and safe in patients with AS and PsA in a real-life setting.
BACKGROUND: Secukinumab (SEC) is effective for ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in randomized trials, but real-life data are lacking. RESEARCH DESIGN AND METHODS: Real-life, prospective observational study on 169 consecutive outpatients at baseline (T0) and at 6 (T6) and 12 months (T12) after starting SEC (39 AS, 23%; 130 PsA, 77%). RESULTS: Significant improvement was seen at T6 and T12 for all clinical variables, including TJC, SJC, ESR, CRP, DAPSA, ASDAS-CRP, and BASDAI, as well as in patient-reported outcomes like VAS-pain. By multivariable regression analysis, in AS patients high BASDAI at T0 correlated with diagnostic delay (R2 = 0.4; p = 0.009) and peripheral joint involvement (R2 = 0.4; p = 0.04). During follow-up, reduction of BASDAI positively correlated with high ESR (R2 = 0.65; p = 0.04). ASDAS-CRP at T0 positively correlated with high ESR (R2 = 0.34; p = 0.004). Reduction of ASDAS-CRP from T0 to T6 correlated with current smoking status (R2 = 0.42; p = 0.003). In PsA patients, reduction of DAPSA score from T0 to T12 is negatively correlated with the presence of metabolic syndrome (R2 = 0.41; p = 0.0025). SEC was well tolerated; 10 patients discontinued treatment for non-severe adverse events. CONCLUSIONS: Secukinumab is effective and safe in patients with AS and PsA in a real-life setting.
Authors: Maria Sole Chimenti; Paola Conigliaro; Francesco Caso; Luisa Costa; Augusta Ortolan; Paola Triggianese; Marco Tasso; Giulia Lavinia Fonti; Maria Grazia Lorenzin; Roberto Perricone; Roberta Ramonda Journal: Clin Rheumatol Date: 2021-08-19 Impact factor: 3.650
Authors: Uta Kiltz; Petros P Sfikakis; Karl Gaffney; Andreas Bounas; Nicola Gullick; Eric Lespessailles; Jan Brandt-Juergens; Rasho Rashkov; Barbara Schulz; Effie Pournara; Piotr Jagiello Journal: Rheumatol Ther Date: 2022-06-08
Authors: Roberta Ramonda; Mariagrazia Lorenzin; Maria Sole Chimenti; Salvatore D'Angelo; Antonio Marchesoni; Carlo Salvarani; Ennio Lubrano; Luisa Costa; Ylenia Dal Bosco; Elena Fracassi; Augusta Ortolan; Mario Ferraioli; Antonio Carriero; Elisa Visalli; Riccardo Bixio; Francesca Desiati; Alberto Bergamini; Elisa Pedrollo; Andrea Doria; Rosario Foti; Antonio Carletto Journal: Ther Adv Musculoskelet Dis Date: 2022-04-29 Impact factor: 3.625
Authors: Roberta Ramonda; Mariagrazia Lorenzin; Antonio Carriero; Maria Sole Chimenti; Raffaele Scarpa; Antonio Marchesoni; Ennio Lubrano di Scorpaniello; Carlo Salvarani; Alberto Cauli; Angelo Semeraro; Leonardo Santo; Augusta Ortolan; Andrea Doria; Elena Fracassi; Giulia Virelli; Marco Masia; Rosalinda Fanizzi; Elisa Visalli; Giorgio Amato; Antonio Carletto; Rosario Foti Journal: RMD Open Date: 2021-02
Authors: Alicia García-Dorta; Paola León-Suarez; Sonia Peña; Marta Hernández-Díaz; Carlos Rodríguez-Lozano; Enrique González-Dávila; María Vanesa Hernández-Hernández; Federico Díaz-González Journal: Front Med (Lausanne) Date: 2022-01-13
Authors: María Aparicio; Carlos A Guillén-Astete; Clementina López-Medina; Carlos Sastre; Fernando J Rodríguez Martínez Journal: Rheumatol Ther Date: 2021-11-27